Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Active Motif, Inc.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 26 May 2006:
Vol. 312. no. 5777, pp. 1165 - 1168
DOI: 10.1126/science.1125948
Prev | Table of Contents | Next

Perspective

Cancer Biomarkers—An Invitation to the Table

William S. Dalton1* and Stephen H. Friend2*

The allure of the emerging genomic technologies in cancer is their ability to generate new biomarkers that predict how individual cancer patients will respond to various treatments. However, productive implementation of cancer biomarkers into patient care will require fundamental changes in how we consider approvals for cancer indications and how we track patient responses. Here we briefly describe ongoing efforts to identify and to validate cancer biomarkers, discuss the technological hurdles that lie ahead, and then focus on the more pressing political and cultural issues that, if left unheeded, could derail many of the anticipated benefits of biomarker research.

1 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33613, USA.
2 Merck Research Laboratories, West Point, PA 19846, USA.

* To whom correspondence should be addressed. E-mail: dalton{at}moffitt.usf.edu (W.S.D.); stephen_friend{at}merck.com (S.H.F.)

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
J. Cummings, C. Hodgkinson, R. Odedra, P. Sini, S. P. Heaton, K. E. Mundt, T. H. Ward, R. W. Wilkinson, J. Growcott, A. Hughes, et al. (2008)
Mol. Cancer Ther. 7, 455-463
   Abstract »    Full Text »    PDF »
Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells.
P. Mallikaratchy, Z. Tang, S. Kwame, L. Meng, D. Shangguan, and W. Tan (2007)
Mol. Cell. Proteomics 6, 2230-2238
   Abstract »    Full Text »    PDF »
Clinical Validity of the Lung Cancer Biomarkers Identified by Bioinformatics Analysis of Public Expression Data.
B. Kim, H. J. Lee, H. Y. Choi, Y. Shin, S. Nam, G. Seo, D.-S. Son, J. Jo, J. Kim, J. Lee, et al. (2007)
Cancer Res. 67, 7431-7438
   Abstract »    Full Text »    PDF »
Translating MicroRNA Discovery Into Clinical Biomarkers in Cancer.
S. A. Waldman and A. Terzic (2007)
JAMA 297, 1923-1925
   Full Text »    PDF »
Is Molecular Profiling Ready for Use in Clinical Decision Making?.
J. P. A. Ioannidis (2007)
Oncologist 12, 301-311
   Abstract »    Full Text »    PDF »
Improved breast cancer prognosis through the combination of clinical and genetic markers.
Y. Sun, S. Goodison, J. Li, L. Liu, and W. Farmerie (2007)
Bioinformatics 23, 30-37
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)